Newsroom Join our team About us Our purpose Our culture Products & pipeline Investors Overview Our products Our pipeline Publications Our pipeline We are committed to building a pipeline of products to address a range of neurological diseases Jennifer, person with Parkinson’s, power puncher Our pipeline On February 1, 2021, the FDA approved a second indication for GOCOVRI as an adjunctive treatment to levodopa/carbidopa in Parkinson’s disease patients experiencing OFF episodes To learn more please read our press release. ADS-4101 in development for the treatment of partial onset seizures in patients with epilepsy (program paused) ADS-4101 is an investigational high-dose, modified release lacosamide capsule, taken once-daily at bedtime. Lacosamide is an anti-epilepsy active ingredient previously approved by the FDA and currently marketed by UCB SA/NV as VIMPAT® (lacosamide). The ADS-4101 development program is currently paused as we are evaluating the potential value and options for a path forward for this candidate. “People are sometimes told to go home and find a comfortable chair. Well, I decided early on to do the opposite.” – John, person with Parkinson’s, determined runner and PD fundraiser Related link See our products Connect with us Contact us Privacy policy Online tracking opt-out guide Terms of use Site map © 2021 Copyright Adamas Pharmaceuticals, Inc. or its related companies. All rights reserved. Please note that our Privacy Policy has recently been updated: Privacy PolicyACCEPT